ahlam1399
08-10-2016, 04:30 PM
UPDATE 1-Lilly cancer drug hits hurdle, panel recommends study continue
Aug 10 (Reuters) - An independent panel's interim analysisof Eli Lilly and Co's breast cancer drug abemaciclibshowed the treatment did **t meet the effectiveness criteria ina late-stage trial.http://feeds.feedburner.com/~ff/reuters/governmentfilingsNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/governmentfilingsNews?a=xTadJZv4vPk:YRS0H9opVII:yI l2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/governmentfilingsNews?i=xTadJZv4vPk:YRS0H9opVII:V_ sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/governmentfilingsNews?a=xTadJZv4vPk:YRS0H9opVII:V_ sGLiPBpWU) http://feeds.feedburner.com/~ff/reuters/governmentfilingsNews?i=xTadJZv4vPk:YRS0H9opVII:F7 zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/governmentfilingsNews?a=xTadJZv4vPk:YRS0H9opVII:F7 zBnMyn0Lo)
http://feeds.feedburner.com/~r/reuters/governmentfilingsNews/~4/xTadJZv4vPk
Aug 10 (Reuters) - An independent panel's interim analysisof Eli Lilly and Co's breast cancer drug abemaciclibshowed the treatment did **t meet the effectiveness criteria ina late-stage trial.http://feeds.feedburner.com/~ff/reuters/governmentfilingsNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/governmentfilingsNews?a=xTadJZv4vPk:YRS0H9opVII:yI l2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/governmentfilingsNews?i=xTadJZv4vPk:YRS0H9opVII:V_ sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/governmentfilingsNews?a=xTadJZv4vPk:YRS0H9opVII:V_ sGLiPBpWU) http://feeds.feedburner.com/~ff/reuters/governmentfilingsNews?i=xTadJZv4vPk:YRS0H9opVII:F7 zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/governmentfilingsNews?a=xTadJZv4vPk:YRS0H9opVII:F7 zBnMyn0Lo)
http://feeds.feedburner.com/~r/reuters/governmentfilingsNews/~4/xTadJZv4vPk